Immunohistochemistry for prostate biopsy - impact on histological prostate cancer diagnoses and clinical decision making
- Mandel, Philipp (PD Dr. med. Dr. rer. nat.)
- Wenzel, Mike (Dr. med.)
- Höh, Robert Benedikt
- Welte, Maria-Noemi
- Preißer, Felix Martin (Dr. med.)
- Inam, Tahir
- Wittler, Clarissa
- Humke, Clara Julia (Dr. med.)
- Köllermann, Jens (PD Dr. med.)
- Wild, Peter Johannes
- Würnschimmel, Christoph
- Tilki, Derya (Prof. Dr.)
- Graefen, Markus (Prof. Dr. med.)
- Kluth, Luis (Dr. med.)
- Karakiewicz, Pierre I.
- Chun, Felix (PD Dr. med.)
- Becker, Andreas
DOIAbstract
Background: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. Methods: Between January 2017–June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. Results: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p 40%. Patients with changes ...
Add to ORKG